Galiellalactone Inhibits Stem Cell-Like Prostate Cancer Cells
Author Information
Author(s): Hellsten Rebecka, Johansson Martin, Dahlman Anna, Sterner Olov, Bjartell Anders
Primary Institution: Lund University
Hypothesis
This study aimed to investigate the effect of galiellalactone on prostate cancer stem cell-like cells.
Conclusion
Galiellalactone effectively decreases the proportion of ALDH+ prostate cancer cells and induces apoptosis in these cells.
Supporting Evidence
- Galiellalactone treatment decreased the proportion of ALDH+ prostate cancer cells.
- ALDH+ cells showed increased tumorigenicity compared to ALDH- cells.
- Treatment with galiellalactone induced apoptosis in ALDH+ cells.
Takeaway
Researchers found that a compound called galiellalactone can kill certain cancer cells that are hard to treat, which might help in fighting prostate cancer.
Methodology
The study used human prostate cancer cell lines and assessed the effects of galiellalactone on ALDH+ cells through various assays including ALDEFLUOR assay, flow cytometry, and tumorigenicity assays in mice.
Limitations
The study primarily focused on in vitro and xenograft models, which may not fully represent human responses.
Statistical Information
P-Value
p=0.0013 for DU145 cells; p=0.0441 for LNCaP-IL6 cells
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website